Comparability: manufacturing, characterization and controls, report of a UK Regenerative Medicine Platform Pluripotent Stem Cell Platform Workshop, Trinity Hall, Cambridge, 14-15 September 2015.

阅读:3
作者:Williams David J, Archer Richard, Archibald Peter, Bantounas Ioannis, Baptista Ricardo, Barker Roger, Barry Jacqueline, Bietrix Florence, Blair Nicholas, Braybrook Julian, Campbell Jonathan, Canham Maurice, Chandra Amit, Foldes Gabor, Gilmanshin Rudy, Girard Mathilde, Gorjup Erwin, Hewitt Zöe, Hourd Paul, Hyllner Johan, Jesson Helen, Kee Jasmin, Kerby Julie, Kotsopoulou Nina, Kowalski Stanley, Leidel Chris, Marshall Damian, Masi Louis, McCall Mark, McCann Conor, Medcalf Nicholas, Moore Harry, Ozawa Hiroki, Pan David, Parmar Malin, Plant Anne L, Reinwald Yvonne, Sebastian Sujith, Stacey Glyn, Thomas Robert J, Thomas Dave, Thurman-Newell Jamie, Turner Marc, Vitillo Loriana, Wall Ivan, Wilson Alison, Wolfrum Jacqueline, Yang Ying, Zimmerman Heiko
This paper summarizes the proceedings of a workshop held at Trinity Hall, Cambridge to discuss comparability and includes additional information and references to related information added subsequently to the workshop. Comparability is the need to demonstrate equivalence of product after a process change; a recent publication states that this 'may be difficult for cell-based medicinal products'. Therefore a well-managed change process is required which needs access to good science and regulatory advice and developers are encouraged to seek help early. The workshop shared current thinking and best practice and allowed the definition of key research questions. The intent of this report is to summarize the key issues and the consensus reached on each of these by the expert delegates.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。